AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm

$400bn tie-up with Bristol Myers Squibb would create world’s fourth largest drugmaker but analysts question rationale for deal More than £17bn was wiped off the value of Britain’s biggest drugmaker, AstraZeneca, on Monday after a report that it was in discussions to take over its US rival Bristol Myers Squibb in a deal

AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.

AstraZeneca stock fell as investors balked at reports of merger talks with Bristol Myers Squibb about forming one of ​the world's biggest drugmakers

Drug giants AstraZeneca, BMS weighing $400 bn tie-up  euractiv.com

Astrazeneca’s share price declined sharply in early trading after investors cast doubt over the potential merger with its US rival. The UK drugmaker’s shares suffered a six per cent decline in early trading to 11,866p, after reports it was exploring a possible $400bn megadeal with Bristol Myers Squibb.  The FTSE 100 gi

The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks  WSJ

The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.

AstraZeneca shares tumble 7% after reported Bristol Myers talks  Reuters

AstraZeneca shares fall on Bristol Myers Squibb merger talks  The Times